MicroRNA-34a Inhibits the Proliferation and Metastasis of Osteosarcoma Cells Both In Vitro and In Vivo by Yan, Kang et al.
MicroRNA-34a Inhibits the Proliferation and Metastasis
of Osteosarcoma Cells Both In Vitro and In Vivo
Kang Yan
., Jie Gao
., Tongtao Yang
., Qiong Ma, Xiuchun Qiu, Qingyu Fan*, Baoan Ma*
Department of Orthopedic Surgery, Tangdu Hospital, Fourth Military Medical University, Xi’an, Shaanxi, People’s Republic of China
Abstract
Background: MicroRNAs (miRNAs) are a class of endogenously expressed, small noncoding RNAs, which suppress its target
mRNAs at the post-transcriptional level. Studies have demonstrated that miR-34a, which is a direct target of the p53 tumor
suppressor gene, functions as a tumor suppressor and is associated with the tumor growth and metastasis of various human
malignances. However, the role of miR-34a in osteosarcoma has not been totally elucidated. In the present study, the effects
of miR-34a on osteosarcoma and the possible mechanism by which miR-34a affected the tumor growth and metastasis of
osteosarcoma were investigated.
Methodology/Principal Finding: Over-expression of miR-34a partially inhibited proliferation, migration and invasion of
osteosarcoma cells in vitro, as well as the tumor growth and pulmonary metastasis of osteosarcoma cells in vivo. c-Met is a
target of miR-34a, and regulates the migration and invasion of osteosarcoma cells. Osteosarcoma cells over-expressing miR-
34a exhibited a significant decrease in the expression levels of c-Met mRNA and protein simultaneously. Finally, the results
from bioinformatics analysis demonstrated that there were multiple putative targets of miR-34a that may be associated with
the proliferation and metastasis of osteosarcoma, including factors in Wnt and Notch signaling pathways.
Conclusion/Significance: The results presented in this study demonstrated that over-expression of miR-34a could inhibit
the tumor growth and metastasis of osteosarcoma probably through down regulating c-Met. And there are other putative
miR-34a target genes beside c-Met which could potentially be key players in the development of osteosarcoma. Since
pulmonary metastases are responsible for mortality of patient carrying osteosarcoma, miR-34a may prove to be a promising
gene therapeutic agent. It will be interesting to further investigate the mechanism by which miR-34a functions as a tumor
suppressor gene in osteosarcoma.
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Introduction
Osteosarcoma (OS) is the most common human primary
malignant bone tumor in children and young adults, which
accounts for approximately 60% of malignant bone tumors in the
first 2 decades of life [1]. It mainly present around regions with
active bone growth and repairation, such as knee joint, lower
femur and upper tibia. With a rapid expansion of our knowledge
about stem cell biology, emerging evidence suggests osteosarcoma
should be regarded as a kind of differentiation disease caused by
genetic and epigenetic changes that interrupt osteoblast differen-
tiation from mesenchymal stem cells. Osteosarcoma is locally
destructive and has a high metastatic potential [2]. The clinical
treatment for osteosarcoma is of great difficulties, and patients
treated with amputation alone often died of pulmonary metastasis
within one year. Thanks to the rapid development of treatment for
high grade osteosarcoma which combines surgery with neoadju-
vant and adjuvant chemotherapy [3], the 5-year survival rate of
patients carrying osteosarcoma has been dramatically improved
[4]. However, the cure rate of patients carrying osteosarcoma is
still very poor and most of them eventually died of pulmonary
metastases [5]. Therefore, in addition to the surgical removal of
the primary tumor and the chemotherapy, the prevention of
pulmonary metastases during the early stage of tumor develop-
ment is also critical for the improvement of the prognosis of
patients carrying osteosarcoma. Gene therapy is one such targeted
technique for application to osteosarcoma and various studies have
been carried out to investigate the genes that are involved in
metastasis of osteosarcoma. However, the highly complex
molecular mechanism of metastasis is still poorly understood.
Nowadays, miRNAs have become a new research hotspot for gene
therapy.
miRNAs (microRNAs) are a class of endogenous, noncoding,
single stranded small regulatory RNA molecules, which are
approximately 22 nucleotides in length [6]. Their coding genes,
which are mainly located in cancer associated genomic regions or
in fragile sites, account for approximately 1% of the entire genome
[7]. miRNAs play an important role in the regulation of gene
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33778expression at the post-transcriptional level. Unlike short interfering
RNAs (siRNAs), miRNAs mainly silence the expression of multiple
genes instead of a single gene. It is estimated that miRNAs have
the potential to regulate at least 20%–30% of all human genes [8],
and that an average miRNA have more than 100 targets [9].
However, their biological function remains largely unknown and
only a few mRNAs that are directly regulated by miRNAs in
animals have been verified empirically. miRNAs are often
deregulated in human malignancies and correlated to the
regulation of many cellular processes including proliferation,
differentiation, apoptosis and metastasis. miRNAs can function as
either oncogenes or tumor suppressors by specifically regulating
the expression of their target genes [10]. Those miRNAs whose
expression is increased in tumors may be considered as oncogenes.
These oncogene miRNAs usually promote tumor development by
negatively regulating tumor suppressor genes. Meanwhile, some
miRNAs whose expression is decreased in tumor are considered as
tumor suppressor genes. Tumor suppressor miRNAs usually
prevent tumor development by negatively regulating oncogenes.
Recently, mounting evidence has indicated that miRNAs are
attractive candidates of upstream regulators in metastatic
progression, because they may regulate a number of invasion
and metastasis-related genes [11,12,13,14,15], suggesting that
miRNAs may be used as a potential therapeutic avenue in
preventing tumor metastasis.
miR-34a is a member of an evolutionarily conserved miRNA
family, miR-34s. miR-34a is a direct transcriptional target of p53
tumor suppressor [16]. The inactivating mutations of p53 often
cause a decreased expression of miR-34a in tumors [17]. miR-34a
functions as a tumor suppressor gene by down-regulating its
targets such as CDK4, CDK6, E2F3, E2F5 et al [18,19]. miR-34a
also plays an important role in the p53-induced cell cycle arrest,
cell senescence, apoptosis and other biological behavior [20]. The
inactivation and absence of miR-34a is related to the pathogenesis
of a variety of tumors [17,21,22], including osteosarcoma [23].
However, the effects of miR-34a on osteosarcoma have not been
totally elucidated. Therefore, it is of great significance to further
study the function and mechanism of miR-34a in Osteosarcoma.
In the present studies, we performed in vitro and in vivo
experiments to evaluate the effects of miR-34a on tumor growth
and metastasis of SOSP-9607 cells, as well as the expression of c-
Met, because c-Met is a direct target of miR-34a and correlated to
the metastasis potential of tumors. We also performed the
prediction of miR-34a putative target genes which are correlated
to tumor growth and metastasis by using bioinformatics analysis.
For the first time, we reported that over-expression of miR-34a
inhibited growth and metastasis of osteosarcoma cells both in vitro
and in vivo. In addition, miR-34a could specifically down-regulate
the expression of the metastasis related gene c-Met, indicating that
miR-34a may function as a tumor gene suppressor through down-
regulating c-Met oncogene. Finally, there are other putative miR-
34a target genes beside c-Met which may mediate the miR-34a
induced inhabitation of tumor growth and metastasis in osteosar-
coma. We supposed that miR-34a may prove to be a promising
gene therapeutic agent which functions as a tumor suppressor gene
through down-regulating multiple target oncogenes in osteosarco-
ma.
Results
1. Plasmid construction and generation of stable cells
To facilitate the investigation of the effects of miR-34a on
osteosarcoma, a has-miR-34a eukaryotic expression vector, named
pcDNA-miR34a, was constructed (Figure 1A). The constructs was
then verified by DNA sequencing (Figure S1). SOSP-9607 cells
were transfected with either pcDNA-miR34a or pcDNA3.1 and
then G418-slected for 6 weeks to generate two stable SOSP-9607
cells (stable SOSP-9607 cells transfected with pcDNA3.1 and
pcDNA-miR34a, respectively). Therefore, experiments with
Figure 1. Plasmid construction and generation of stable cells.
(A) Schematic representation of miR-34a expression vector. (B) Relative
miR-34a expression levels in three groups of SOSP-9607 cells (Blank,
SOSP-9607 cells; control, stable SOSP-9607 cells transfected with
pcDNA3.1; miR-34a, stable SOSP-9607 cells transfected with pcDNA-
miR34a.). (C) Relative miR-34a expression levels in SAOS-2 cells
transiently transfected with pcDNA3.1 and pcDNA-miR34a respectively.
U24 small nucleolar RNA (RNU24) was used as an internal loading
control to normalize the results. Data are presented as means6SD.
*P,0.01 (n=3) is considered as statistically significant.
doi:10.1371/journal.pone.0033778.g001
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(SOSP-9607 cells), control group (stable SOSP-9607 cells
transfected with pcDNA3.1) and miR-34a group (stable SOSP-
9607 cells transfected with pcDNA-miR34a).
The miR-34a expression levels in three groups were measured
using Stem-loop Real-time RT-PCR. The results showed that
cells in miR-34a group expressed a higher level of miR-34a as
compared with control group and blank group,respectively.
However, we did not find significant difference between control
group and blank group (Figure 1B). The miR-34a expression levels
in SAOS-2 cells transiently transfected with either pcDNA3.1 or
pcDNA-miR34a was also measured, and a similar result was
shown (Figure 1C). These results indicated that pcDNA-miR34a
can up-regulate miR-34a expression in both SOSP-9607 cells and
SAOS-2 cells, which facilitated the further study of miR-34a
functions in osteosarcoma.
2. miR-34a inhibits proliferation of osteosarcoma in vitro
To investigate the effects of miR-34a on the proliferation of
osteosarcoma cells, MTT assay was performed following the
procedure described in Methods every 24 h. And then prolifer-
ation curve was depicted. The results demonstrated that cells in
miR-34a group exhibited significant declines in proliferation
capacity as compared with cells in control group and blank group,
which exhibits a negative relationship with the exogenous miR-
34a level (Figure 2A). We also tested SAOS-2 cells transiently
transfected with either pcDNA3.1 or pcDNA-miR34a (Figure 2B)
and SOSP-9607 cells transiently transfected with either miR-34a
mimics or inhibitors (Figure S2A, B). The results were similar to
that of stable transfected SOSP-9607 cells.
3. miR-34a inhibits migration and invasion of
osteosarcoma in vitro
It has been reported that hepatocellular carcinoma cells
transfected with miR-34a mimics are inhibited of both migration
and invasion [24], and the expression of miR-34a is associated
with the tumorigenesis of osteosacoma [23]. However, there is
no study on the role of miR-34 in osteosarcoma metastasis.
Therefore, in this part, we performed transwell migration and
invasion assay to investigate the effects of miR-34a on the
migratory and invasive behaviors of osteosarcoma cells in vitro.
The results demonstrated that cells in miR-34a group exhibited
significant declines in migration and invasion capacities as
compared with cells in control group and blank group respectively
(Figure 3A, B, C, D). However, there is no significant difference
between blank group and control group. We also tested SAOS-2
cells transiently transfected with either pcDNA3.1 or pcDNA-
miR34a (Figure 3E, F, G, H) and SOSP-9607 cells transiently
transfected with either miR-34a mimics or inhibitors (Figure 2C,
D, E, F), the results were similar to that of stable transfected
SOSP-9607 cells. , strongly indicated that miR-34a was an
important participant in the reduction of migratory and invasive
potential of osteosarcoma in vitro.
4. miR-34a inhibits tumor growth of osteosarcoma in vivo
Given these findings in vitro, animal studies were conducted to
further evaluate the effect of miR-34a on orthotopic tumor growth
in athymic nude mice. Two groups of stable transfected cells
(control group, stable SOSP-9607 cells transfected with
pcDNA3.1; and miR-34a group, stable SOSP-9607 cells trans-
fected with pcDNA-miR34a) were injected into proximal tibia of
young nude mice as described in methods, respectively.
To evaluated tumor growth, the length (L) and width (W) of
orthotopic tumor were measured every 7 days post inoculation.
The volume of tumor was calculated according to the formula:
volume=1/26L6W
2, and the growth curve of orthotopic tumor
was depicted. The results demonstrated that cells in control group
formed progressively growing solid tumors in all mice. By contrast,
cells in miR-34a group produced much smaller tumors (Figure 4A,
C). 42 days after inoculation, the mice were sacrificed and the
orthotopic tumors were harvested and weighed. The mean tumor
weight6SD of orthotopic tumors were as follows: miR-34a group
1.13260.177 g, control group 1.76860.341 g (Figure 4B, D).
Meanwhile, the miR-34a expression levels in the orthotopic
tumors were also tested, and the result showed that the orthotopic
tumors in the miR-34a group expressed higher miR-34a levels as
compared with control group (Figure 4E). Both of the results
indicated that ectogenous miR-34a can significantly inhibit the
tumor growth of osteosarcoma in vivo.
Figure 2. miR-34a inhibits proliferation of osteosarcoma in
vitro. Every 24 h, MTT assay was performed on three groups of SOSP-
9607 cells (Blank, SOSP-9607 cells; control, stable SOSP-9607 cells
transfected with pcDNA3.1; miR-34a, stable SOSP-9607 cells transfected
with pcDNA-miR34a) and SAOS-2 cells (pcDNA3.1, SAOS-2 cells
transiently transfected with pcDNA3.1; pcDNA-miR34a, SAOS-2 cells
transiently transfected with pcDNA-miR34a) respectively (A, B). The
viable cell number was evaluated as the value of the absorbance at
490 nm with a reference wavelength of 630 nm. Values of optical
density (OD) are expressed as means6SD. *P,0.05, ** p,0.01 (n=3)
are considered as accepted as statistically significant.
doi:10.1371/journal.pone.0033778.g002
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osteosarcoma in vivo
To evaluate the pulmonary metastasis potential of cells in miR-
34a group and control group, 42 days after inoculation, the mouse
lungs in both groups were harvest and the tumor nodules on the
surface of the lung were counted and photographed (Figure 5A).
An average of 26.2612.4 metastatic tumor nodules were detected
per lung in miR-34a group, while mice in control group produced
an average of 96.7620.5 metastatic tumor nodules per lung
(Figure 5B), indicating that miR-34a significantly decreased tumor
colonization in the lung.
Histological examination of the lung sections showed that most
of the tumor nodules were organized in a predominantly
peripheral distribution in both groups. However,there was a
significant difference in tumor nodules concentration and size in
lung histology sections. The lungs of miR-34a group mice
contained less and smaller spontaneous metastases as comparing
with control group (Figure 5C). Taken together, these results
strongly suggest that miR-34a can inhibit osteosarcoma metastasis
and might be prevention of metastasis and recurrence in
osteosarcoma patients.
Figure 4. miR-34a inhibits tumor growth of osteosarcoma in
vivo. The results showed that the growth velocities of orthotopic
tumors in miR-34a group (stable SOSP-9607 cells transfected with
pcDNA-miR34a.) decreased as compared with control group (stable
SOSP-9607 cells transfected with pcDNA3.1). (A)R e p r e s e n t a t i v e
photographs of tumors (arrows) on the left legs of mouse. (B)
Representative photographs of orthotopic tumors harvested 42 days
after inoculation. (C) Tumor growth curves measured after the
inoculation. The length (L) and width (W) of tumor measured every 7
days after inoculation, and the volume of tumor was calculated
according to the formula: volume=1/26L6W
2.( D) Orthotopic tumor
weights 42 days after inoculation. Data are presented as means6SD. (E)
42 days after inoculation, miR-34a expression levels in Orthotopic
tumors were tested and showed in relative miR-34a levels. *P,0.05,
** P,0.01 (n=6) are considered as statistically significant.
doi:10.1371/journal.pone.0033778.g004
Figure 5. miR-34a inhibits pulmonary metastasis of osteosar-
coma in vivo. (A) Representative macroscopic pictures of mouse
lungs, 42 days after inoculation. (B) Graph displaying the total number
of tumor nodules per lung in control group (stable SOSP-9607 cells
transfected with pcDNA3.1) and miR-34a group (stable SOSP-9607 cells
transfected with pcDNA-miR34a.). Data are presented as means6SD.
*P,0.01 (n=6) is considered as statistically significant. (C) Represen-
tative photographs of H&E stained spontaneous lung metastases. The
results showed that most of the tumor nodules were organized in a
predominantly peripheral distribution in both groups. However, tumor
nodules (arrows) in miR-34a group were smaller and distributed in a
lower concentration as comparing with control group.
doi:10.1371/journal.pone.0033778.g005
Figure 3. miR-34a inhibits migration and invasion of osteosarcoma in vitro. Representative photographs of migrated and invaded SOSP-
9607 cells (Blank, SOSP-9607 cells; control, stable SOSP-9607 cells transfected with pcDNA3.1; miR-34a, stable SOSP-9607 cells transfected with
pcDNA-miR34a) on the membrane at a magnification of 1006(A, B). Quantitative results for the migration and invasion ability of each group of
SOSP-9607 cells were shown as migrated and invaded cell number, 16 h after incubation (C, D). Representative photographs of migrated and
invaded SAOS-2 cells (pcDNA3.1, SAOS-2 cells transiently transfected with pcDNA3.1; pcDNA-miR34a, SAOS-2 cells transiently transfected with
pcDNA-miR34a) on the membrane at a magnification of 1006(E, F). Quantitative results for the migration and invasion ability of SAOS-2 cells were
shown as migrated and invaded cell number, 16 h after incubation (G, H). Data are expressed as means6SD. *P,0.01 (n=3) is considered as
statistically significant.
doi:10.1371/journal.pone.0033778.g003
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migration and invasion of osteosarcoma cells
Studies have reported that miR-34a directly repressed the
expression of c-Met in HeLa cells [16], suppressed brain tumor
growth by targeting c-Met [25], and acted as a tumor suppressor
in uveal melanoma cell proliferation and migration through the
down-regulation of c-Met [26]. However, considering that the
miR-34a-c-Met pathway may show different patterns in different
cell backgrounds, we further investigated whether over-expression
of miR-34a also down-regulated the expression of c-Met in
osteosarcoma cells. We detected the mRNA level of c-Met by RT-
PCR and the -protein levels of c-Met by western blotting in three
groups of stable SOSP-9607 cells. The results from Western
blotting demonstrated that the endogenous c-Met protein level in
miR-34a group cells exhibited remarkable decrease as compared
with blank and control groups respectively (Figure 6A). The results
from RT-PCR demonstrated that the endogenous c-Met mRNA
level in miR-34a group cells was also significantly decreased
(Figure 6B). These results together indicate that miR-34a down-
regulates c-Met expression in osteosarcoma at the translational
level and reduces mRNA stability simultaneously.
We also repeated the luciferase assay to validate c-met as a
target of miR-34a in osteosarcoma cells SOSP-9607, and tested
whether c-Met inhibits the migration and invasion of SOSP-9607
cells as that in other cells. The results demonstrated that, in SOSP-
9607 cells, the luciferase activity of the pmiR-Met UTR-Wt
construct was significantly inhibited after the introduction of miR-
34a, similar to those reported by others [27]. Meanwhile,
mutations of the two c-Met 39UTR-binding sites abolished the
ability of miR-34a to regulate luciferase expression (Figure 6C).
And as expected, c-Met siRNA significantly inhibited the
migration and invasion of SOSP-9607 -cells (Figure 6D, E).
7. Putative Targets of miR-34a
Bioinformatics methods based on sequence similarity between
miRNAs and mRNAs were used to predict the putative target
genes of miR-34a. We predicted putative miR-34a target genes by
using online softwares, such as TargetScan 5.1 and PicTar, and
finally obtained several putative target genes that are correlated
with the tumor growth or metastasis (Table 1, 2).
Discussion
A large body of evidence has indicated that miRNAs are
frequently deregulated in a variety of human malignancies [28].
Studies showed a direct link between miRNA function and
oncogenesis which is supported by examining the expression of
miRNAs in clinical samples [29,30]. The profiling of miRNA
expression showed that most of them are down-regulated in
tumors compared to normal tissues [31], like let-7 in lung cancers
[32] and miR-127 in human bladder cancers [33]. However, there
are other miRNAs which are up-regulated in tumors, like miR-150
in gastric cancer [34], miR-21 in prostate cancer [35] and miR-17-
92 cluster in renal cell carcinoma [36]. We focused on miR-34a
because not only previous reports demonstrated that the
expression of miR-34a was significantly decreased in primary
osteosarcoma samples as compared with adjacent normal tissues
[23], but also the mutations of p53 tumor suppressor gene, which
directly regulates the expression of miR-34a, was also found in 20–
60% of sporadic osteosarcomas [16,37]. Both of the previous
reports suggested that miR-34a may function as a tumor
suppressor in osteosarcoma.
miR-34a is a member of an evolutionarily conserved miRNA
family, miR-34s. Initial links to tumorigenesis emerged from
Figure 6. c-Met is a target of miR-34a, and regulates the
migration and invasion of osteosarcoma cells. (A) Western
blotting analysis of c-Met protein expression. (B) qRT-PCR analysis of c-
Met mRNA expression. The mRNA levels of c-Met in three groups of
SOSP-9607 cells (blank, SOSP-9607 cells; control, stable SOSP-9607 cells
transfected with pcDNA3.1; miR-34a, stable SOSP-9607 cells transfected
with pcDNA-miR34a.) were normalized against that of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) which served as an internal
control. (C) The result from luciferase assay showed that the luciferase
activity of the pmiR-Met UTR-Wt construct was significantly inhibited
after the introduction of miR-34a mimics. Meanwhile, mutations of the
two c-Met 39UTR-binding sites abolished the ability of miR-34a to
regulate luciferase expression. (D, E) SOSP-9607 cells were transiently
transfected with 100 nM of c-Met siRNA or inhibitor NC (Genepharma,
China), respectively. 48 h later, the migration and invasion assay were
performed. Quantitative results for the effects of c-Met siRNA on the
migration and invasion ability of SOSP-9607 cells were shown as
migrated and invaded cell number. The results are presented as
means6SD. *P,0.01 (n=3) is accepted as statistically significant.
doi:10.1371/journal.pone.0033778.g006
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chromosome 1p36, is correlated with tumor occurrence and
frequently missed in human neuroblastoma [38]. miR-34 family
are direct transcriptional targets of p53 tumor suppressor [16].
There is a highly conserved p53 binding site which is
approximately 30 kb above the miR-34a encoding gene [39].
The inactivating mutations of p53 often cause a decreased
expression of miR-34a in tumors [17]. miR-34a plays its tumor
inhibitory effect by down-regulating its targets such as CDK4,
CDK6, E2F3, E2F5 et al [18,19]. miR-34a also plays an
important role in the p53-induced cell cycle arrest, cell senescence,
apoptosis and other biological behavior [20]. The inactivation and
absence of miR-34a is related to the pathogenesis of a variety of
tumors [17,21,22], including osteosarcoma [23]. Moreover, Li et
al. found that miR-34a inhibits migration and invasion of human
hepatocellular carcinoma cells [24]. Pang et al. found that MiR-
34a suppresses invasion of cervical carcinoma and choriocarcino-
ma cells [40]. However, the functions of miR-34a in osteosarcoma
have not been totally elucidated.
Uncontrolled cell proliferation and aggressive tumor cell
metastasis are two essential steps during cancer progression. The
former lead to the orthotopic tumor growth, and the latter
promote tumor transfering to distant sites. Therefore, in this study
we investigated the effects of miR-34a on tumor growth and
metastasis of osteosarcoma. we demonstrated that over-expression
of miR-34a significantly suppresses proliferation,migration and
invasion of SOSP-9607 cells in vitro. These results indicate that
miR-34a plays an important role in the development of
osteosarcoma. However, we can’t imprudently assume that miR-
34a would also have biological activity in vivo. Therefore, we
chose a mouse model to further investigate effects of miR-34a on
tumor growth and pulmonary metastasis. The results demonstrat-
ed that miR-34a also significantly inhibited the capacities of
orthotopic tumor growth and lung metastasis in vivo. Because we
couldn’t maintain the G418 selection in vivo, the selected cells
may not maintain miR-34a over-expression as that in vitro. So, we
further tested the miR-34a expression levels in the orthotopic
tumors 6 weeks after inoculation. The result showed that the miR-
34a expression level of G418 sellected cells, in the orthotopic
tumors after 6 weeks of inoculation, was indeed over-expressed as
that in vitro. Therefore, up-regulated expression of miR-34a was
very effective on inhibiting the tumor growth and metastasis
behaviors of osteosarcoma cells both in vitro and in vivo. These
results indicate that miR-34a functions as a tumor suppressor gene
and can be used as a potential target in the gene therapy of
osteosarcoma.
Metastatic models of tumorigenesis are crucial to understand
the Metastatic behavior of cancer. However, the Metastatic
models of osteosarcoma in experimental animals are rare. Usually,
the metastatic models were conducted in nude mouse by injecting
human osteosarcoma cells either intravenously or subcutaneously
[41]. However, these models are not clinically relevant because
osteosarcoma cells are not spontaneously arisen and will not grow
in the site with proper microenvironment [42]. In this study, we
choose a spontaneous metastatic model, in which orthotopic
ransplantation of osteosacoma cells were performed and then
spontaneous pulmonary metastases were observed [43,44]. The
Table 1. Putative Targets of miR-34a.
Putative targets Software Fuctions and Pathways
BCL6 pictar proliferation; apoptosis.
CCNE2 pictar cell cycle; metastasis.
CD97 targetscan cell motility; cell adhesion.
CSNK1G3 pictar Wnt signaling pathway.
CTNND1 pictar cell adhesion; Wnt signaling pathway.
DLL1 pictar cell adhesion; Notch signaling pathway.
DKK1 miRanda Wnt signaling pathway.
GAS1 targetscan apoptosis; cell cycle arrest; proliferation.
IGFBP3 pictar apoptosis; proliferation.
LEF1 pictar Wnt signaling pathway.
PGEA1 miRanda Wnt signaling pathway.
POFUT1 pictar angiogenesis; Notch signaling pathway.
R-RAS pictar cell adhesion; cell migration.
RUNX2 TargetScan cell proliferation; cell migration.
UHRF2 Pictar cell cycle; proliferation.
VCL pictar Cell migration; cell adhesion.
VEGFA Targetscan Angiogenesis.
doi:10.1371/journal.pone.0033778.t001
Table 2. Experimentally identified Targets of miR-34a.
Experimental identified targets Software Functions and pathways
BCL2 pictar proliferation; apoptosis.
CCND1 pictar cell cycle arrest; proliferation; cell migration; Notch signaling pathway; Wnt signaling pathway.
CDK6 pictar cell cycle arrest; Proliferation.
E2F3 [38][40] pictar cell cycle arrest; proliferation.
JAG1 pictar Proliferation; Cell Invasion; Notch signaling pathway.
Mek1 pictar cell motility; proliferation.
MET pictar Proliferation; cell invasion.
MYCN miRanda Apoptosis; cell cycle; proliferation.
NOTCH1 Pictar Proliferation; cell invasion; Notch signaling pathway.
NOTCH2 pictar Proliferation; Notch signaling pathway.
SIRT1 pictar Cell cycle arrest; Apoptosis; tumor growth; Notch signaling pathway.
WNT1 pictar Proliferation; cell migration; Wnt signaling pathway
doi:10.1371/journal.pone.0033778.t002
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course of osteosarcoma in this animal model, because the micro-
environment of nude mice tibia is similar to the actual situation.
Moreover, with this model, we can study the properties of
orthotopic tumor growth and spontaneous pulmonary metastasis
of osteosarcoma cells simultaneously.
The Receptor tyrosine kinase (RTK) c-Met is a cell surface
receptor for hepatocyte growth factor (HGF) [45]. The Met
oncogene is up-regulated in a variety of tumor cells similar in
scope to p53 mutants [46,47]. HGF-mediated activation of c-Met
results in a complex genetic program referred to as ‘‘invasive
growth’’, including proliferation, invasion, and angiogenesis
[48,49]. In tumor cells, c-Met activation triggers a diverse series
of signaling cascades resulting in cell growth, proliferation,
invasion, and protection from apoptosis [50]. Studies have shown
that miR-34a suppresses brain tumor growth by targeting c-Met
and Notch [25], suppresses proliferation and migration through
the down-regulation of c-Met in uveal melanoma cells [26], and
inhibits migration and invasion through down-regulation of c-Met
expression in human hepatocellular carcinoma cells [24]. The
activities associated with Met signalling including migration,
invasion and colony formation in soft agar were blocked by a
small molecule Met inhibitor [51]. Therefore, in SOSP-9607 cells,
we further investigated whether over-expression of miR-34a also
down-regulated the expression of c-Met and whether c-Met
inhibited the migration and invasion as that in other cells. We
examined the c-Met expression level of osteosarcoma cells in three
groups SOSP-9607 cells, and observed a significant decrease of c-
Met mRNA and protein levels in miR-34a group cells as
compared with blank group and control group. As expected, c-
Met also regulated the migration and invasion of SOSP-9607 cells,
and c-Met is indeed a direct target of miR-34a in SOSP-9607 cells.
These results indicated that miR-34a may suppress tumor growth
and metastasis in osteosarcoma cells through down-regulating c-
Met oncogene. It is supposed that the miR-34a-c-Met pathway
might be a general regulator of tumor growth and metastasis in a
wide range of human malignances, including brain tumor, uveal
melanoma, hepatocellular carcinoma and osteosarcoma.
Unlike siRNAs which silence the expression of a single gene,
miRNAs mainly silence the expression of multiple genes simulta-
neously. It is estimated that an averagemiRNA have more than 100
targets [9], and miRNAs have the potential to regulate at least
20%–30% of all human genes [8]. It is likely that miR-34a may also
regulate other genes beside c-Met. Therefore, to thoroughly
understand the regulatory mechanism of miR-34a in osteosarco-
ma,it is critical to identify more target genes that mediate the miR-
34a induced regulation of tumor growth and metastasis.
Predicting and identifying the miR-34a-targeting genes offer
experimental basis for further research on regulatory mechanism
of miR-34a. By using TargetScan 5.1 and PicTar, we predicted
putative genes of miR-34a which have not been experimentally
identified yet, and finally obtained several putative targets which
are correlated with tumor growth or metastasis, such as BCL6,
CCNE2, CD97, CSNK1G3, CTNND1, DLL1, DKK1, GAS1,
IGFBP3, LEF1, PGEA1, POFUT1, R-RAS, RUNX2, UHRF2,
VCL, VEGFA, etc. (Table 1).
And then, we reviewed experimentally identified miR-34a
target genes, such as BCL2 [52], CCND1 [18],CDK6 [18], E2F3
[38], JAG1 [40], Mek1 [53], MET [25], MYCN [54], NOTCH1
[55], NOTCH2 [55], SIRT1 [56], WNT1 [57] et al (Table 2).
Among them, there are several genes, which mediate the
inhibition of miR-34a induced metastasis in human malignances,
such as Notch1 and JAG1 in cervical carcinoma and choriocar-
cinoma cells [40] and c-Met in in human hepatocellular
carcinoma cells [24]. Meanwhile, there are several genes which
mediate the miR-34a induced tumor growth inhibition, such as
BCL2, E2F3 and MYCN in neuroblastoma [52,54], mitogen-
activated protein kinase kinase 1 (MEK1) in human chronic
myelocytic leukemia cell line K562 [53] and SIRT1 in prostate
cancer PC3 cells [58].
The dysregulation of several evolutionarily conserved signaling
pathways in osteosarcoma tumor samples and cell lines have been
repeatedly found. These signaling pathways include the Hedgehog
(Hh), TGF-b/BMP, ERBB, Notch and Wnt signaling pathways.
Notch signaling pathway participates in a variety of cellular
processes, including cell fate specification, differentiation, prolif-
eration, apoptosis, adhesion, epithelial-mesenchymal transition,
migration, and angiogenesis. Activation of Notch signaling
contributes to the pathogenesis of human osteosarcomas andthe
inhibition of the Notch signaling may be a therapeutic approach
for the treatment of osteosarcoma [59]. Wnt signaling pathway
plays an important role in regulating cell proliferation and
differentiation. Deregulation of Wnt signaling pathway has been
implicated in many human diseases, ranging from cancers to
skeletal disorders [60]. Dickkopf 3 inhibits invasion and motility of
osteosarcoma cells SAOS-2 by modulating the Wnt-beta-catenin
pathway [61]. Interestingly, many genes in Notch and Wnt
signaling pathways are putative targets of miR-34a. For instance,
CCND1, CSNK1G3, CTNND1, DKK1, LEF1, PGEA1 and
WNT1 are members of Wnt signaling pathway, while CCND1,
DLL1, JAG1, NOTCH1, NOTCH2, POFUT1 and SIRT1 are
members of Notch signaling pathway (Table 1, 2). Therefore, we
inferred that miR-34a may play an important role in inhibiting
tumor metastasis and proliferation through down-regulating
multiple target genes, including genes in Notch and Wnt signaling
pathways.
In conclusion, the results presented here demonstrated that
miR-34a has great biological effects on the growth and metastasis
of osteosarcoma cells both in vitro and in vivo. Over-expression of
miR-34a down-regulated the expression of c-Met protein and
mRNA simultaneously, suggesting that miR-34a functions as
tumor suppressors probably through down-regulating c-Met in
osteosarcoma. Furthermore, there are other putative miR-34a
target genes which could potentially be key players in the growth
and metastasis of osteosarcoma cells. However, these putative
targets should be further verified to provide conclusive evidence.
Finally, because pulmonary metastases are responsible for
mortality of patient carrying osteosarcoma, miR-34a may prove
to be a promising gene therapeutic agent. It will be interesting to
verify the putative target genes and further investigate the
mechanism by which miR-34a functions as a tumor suppressor
gene in osteosarcoma.
Materials and Methods
Ethics statement
All the animal operations were performed under the rules
provided by Declaration of Helsinki and approved by the Animal
and Ethics Review Committee, Fourth Military Medical Univer-
sity, Xi’ an, Shaanxi, China (approval ID:2009043). The
anesthesia method and orthotopic transplantation procedures
were based on the methods reported previously [62,63].
Cell culture
Human osteosarcoma cells SOSP-9607 and SAOS-2 were
established and reserved in our laboratory as described previously
[43,64]. SOSP-9607 cells was maintained in RPMI 1640 medium
(HyClone, USA) supplemented with 10% fetal bovine serum (FBS)
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100 ug/ml streptomycin, and incubated at 37uC in humidified
incubator supplemented with 5% CO2 and 95% air. SAOS-2 cells
were maintained in the same conditions, except that DMEM
medium was used.
Plasmid construction and generation of stable cells
The procedure of miR-34a eukaryotic expression vector
construction was referred to the method described previously
[65]. In brief, an approximately 389 base pairs (bp) DNA
fragment, which covering the pri-miR-34a (HGNC:31635;
MIM:611172; miRBase:MI0000268) and native flanking se-
quence, were PCR-amplified from SOSP-9607 genomic DNA
using the following primers: Pri-miR34a FP/BamHI, 59- CGG
GAT CCC CTC CTG CAT CCT TTC TTT -39; Pri-miR34a
RP/HindIII, 59- CGG AAT TCC CTG TGC CTT TTT CCT
TCC -39. The correct sequences of amplified fragment were
verified by sequencing, double digested with HindIII and BamHI,
and cloned into pcDNA3.1 vector (Invitrogen), carrying neomycin
resistance gene. The constructs was then verified by DNA
sequencing.
Transfection was performed using the Lipofectamine
TM 2000
transfection reagent (invitrogen) according to the manufacturer’s
instructions. For establishing stable transfectants, SOSP-9607 cells
were transfected with either pcDNA-miR34a vector or pcDNA3.1
vector. 24 h after transfection, the tansfected cells were selected for
6 weeks in the presence of G418 at a concentration of 400 ug/ml.
The stable transfectants were then expanded and the expression of
miR-34a was evaluated by real time RT-PCR.
Reverse transcription and quantitative real-time PCR
Total RNA containing miRNA and mRNA was extracted from
cells with Trizol Reagent (Invitrogen), or from paraformalin-fixed,
paraffin-embedded (FFPE) tissues withRecoverAll
TM Total Nucleic
Acid Isolation Kit (Ambion, Catalog Number: AM1975), according
to the manufacturer’s instructions. All RNA extractions were
carried out in designated sterile laminar flow hood using RNase/
DNase-free laboratory ware. The integrity and purity of total RNA
was verified by UV spectrophotometry and gel-electrophoresis on
formaldehyde denaturation gel. RNA extraction, and qRT assay
were performed in separate designated rooms to prevent cross-
contamination.
For evaluating the miR-34a expressing levels, quantification
using the TaqMan microRNA assays was performed using two-
step RT-PCR according to the manufacturer’s instructions. In the
reverse transcription (RT) step, cDNA was reverse transcribed
from total RNA sample using specific miR-34a primers from the
Taqman MicroRNA Assays kit (Applied Biosystems, Product ID:
000426) and reagents from the TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems, Part Number: 4366596).
In the Polymerase Chain Reaction (PCR) step, PCR products
were amplified from cDNA samples using the Taqman Micro-
RNA Assays kit together with the TaqMan Universal PCR Master
Mix (Applied Biosystems, Part Number: 4304449). The real-time
PCR results were normalized against an internal control U24
small nucleolar RNA (RNU24), and then expressed as fold
changes.
For evaluating the c-Met expressing levels, 1 ug of total RNA
was used for reverse transcription with iScript cDNA Synthesis Kit
(Bio-Rad, USA) according to the manufacturer’s instructions.
Quantitative RT-PCR was performed with iQ SYBR Green
Supermix (Bio-Rad,USA) according to the manufacturer’s in-
structions on Real-time PCR Instrument ABI-PRISM 7000
(Applied Biosystems, CA). The sequences of the forward and
reverse primers for c-Met were 59- ACT CCC CCT GAA AAC
CAA AGC C -39 and 59- GGC TTA CAC TTC GGG CAC TTA
C- 3 9. The sequences of the forward and reverse primers for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were 59-
AGC CAC ATC GCT CAG ACA -39 and 59- GCC CAA TAC
GAC CAA ATC C -39. The expression level GAPDH was used as
an internal control to normalize the amount of cDNA used for
each PCR reaction. The real-time PCR results were presented as
c-Met mRNA intensity/GAPDH mRNA intensity and then
expressed as fold changes.
Cell proliferation assay by methyl thiazole tetrazolium
Cells proliferation capacity was evaluated with an MTT assay,
which was performed following standard procedure in 96-well
plates. In brief, cells were seeded at a density of 2,000 cells per well
containing 100 ul of culture medium and cultured overnight.
Every 24 h interval, 20 ul of 5 mg/ml MTT(Dimethyl thiazolyl
diphenyl tetrazolium, Sigma)reagent was added to each well and
cells were further incubated for 4 h at 37uC. Then medium was
removed, and 100 ul of DMSO (dimethyl sulfoxide) was added to
each well to dissolve the formazan. The optical density (OD) was
evaluated by measuring the absorbance, with a test wavelength of
490 nm and a reference wavelength of 630 nm. Wells without cells
(DMSO alone) were used as blanks. There were 6 wells in each
group, the experiments were repeated three times independently
and the results were given as means6SD.
Migration and invasion assay
The invasive potential of cells was measured in 6.5 mm
Transwell with 8.0 mm Pore Polycarbonate Membrane Insert
(cat. 3422, Corning, NY) according to the manufacturer’s
instructions. The filter of top chamber was matrigel-coated with
50 ul of diluted matrigel following the standard procedure and
incubated at 37uC for 2 h. The lower chambers were filled with
600 ul of RPMI medium 1640 containing 5% fetal bovine serum
(FBS) as chemoattractant. Cells were serum-free-starved overnight,
and then harvested and resuspended in migration medium (RPMI-
1640 medium with 0.5% BSA). Then the suspension of 5,000 cells
in 100 ul migration medium was added into each top chamber.
After the cells were incubated for 16 h, the non-invading cells that
remained on the upper surface were removed with a cotton swab.
The invasive cells on the lower surface of the membrane insert
were fixed with 4% paraformaldehyde for 30 min, permeabilized
with 0.2% Triton X-100 at room temperature for 15 min, and
then stained with 0.1% crystal violet for 5 min. The number of
cells on the lower surface, which had invaded through the
membrane, was counted under a light microscope in five random
fields at a magnification of 1006. The experiments were repeated
three times independently and results were given as means6SD.
The procedure for transwell migration assays were the same as
the transwell invasion assay except that the filter of top chamber
was not coated with matrigel.
Animals and operative procedure
Four-week-old female nude mice (BALB/c, nu/nu; animal
centre of the Fourth Military Medical University in China
(FMMU)), 17.0–22.0 g in weight,were maintained under specific
pathogen-free conditions with 12-h light/12-h dark cycle at 26–
28uC and 50–65% humidity. Animal feed and underpad, which
were purchased from Experimental Animal Center of Fourth
Military Medical University, were autoclaved and vacuum packed.
The water was adjusted to the PH-value of 2.8 and autoclaved
before use.
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tumor growth and spontaneous pulmonary metastasis properties
of osteosarcoma cells in vivo. In brief, two groups SOSP-9607
cells (control group, stable SOSP-9607 cells transfected with
pcDNA3.1; miR-34a group, stable SOSP-9607 cells transfected
with pcDNA-miR34a) were harvested by treatment with
trypsin-EDTA (Invitrogen), washed twice with PBS, and
resuspended in PBS. Then osteosarcoma cells suspension of
100,000 cells in 100 ul were injected into the proximal tibia of
each anesthetized nude mice (n=6 animals per group). Every 7
days post inoculation, the length and width of individual
orthotopic tumor from each mouse were measured with
c a l i p e r s ,a n dt h ev o l u m e( m m
3) of orthotopic tumor was
calculated according to the formula: 1/26 length 6 width
2
[66], where length is the longer diameter, and width the shorter
one. The curve of orthotopic tumor growth was depicted. 42
days after inoculation, mouse lungs and orthotopic tumors were
harvested. Then the orthotopic tumors were weighed, the miR-
34a expression levels in the orthotopic tumors were tested by
real time RT-PCR, and the number of pulmonary matastatic
tumor nodules was counted under a low-powered dissecting
stereomicroscope. Finally, mouse lungs were fixed with 10%
neutral-buffered formalin, embedded in paraffin, sectioned at
6 um and stained with H&E (hematoxylin and eosin). The
pulmonary metastases were imaged under a light microscope at
a magnification of 1006.
Protein extraction and western blotting analysis
Total proteins were extracted from the cells using RIPA buffer
with 0.5% sodium dodecyl sulfate (SDS) in the presence of 3%
proteinase inhibitor cocktail (Sigma, St. Louis, MO, USA). After
being lysed on ice for 30 min, the lysate was centrifuged at
12,000 rpm for 20 min, and the supernatant was collected for
experiments.
For western blotting, 10 mg of Lysate was separated by 10%
sodium dodecyl sulfate polyacrylamide gel electrophoresis and
transferred onto a nitrocellulose membrane (Invitrogen, Carlsbad,
CA, USA). The membranes were blocked for 1 hour in TBST
with 5% BSA at room temperature, and then incubated overnight
at 4uC in TBST containing 5% BSA and following antibodies: c-
Met antibody (Cat. Ab10728, abcam, China); b-actin antibody
(Cat.ab3280, abcam, China). Membranes were washed 3 times in
TBST, and incubated with a secondary antibody conjugated with
horseradish peroxidase in TBST with 0.5% BSA for 2 hour at
room temperature. After washed 3 times with TBST, bands were
detected by chemiluminescence using Pierce ECL Western
Blotting Substrate (cat. 32109, Pierce, USA). Intensity of the
bands was detected and analyzed using Quantity One analyzing
system (Bio-Rad, USA).
Luciferase reporter assay
For validation of c-Met as a target genes of miR-34a in
osteosarcoma cells, luciferase assay was performed as described
previously [26].
Target prediction
The prediction of miR-34a putative target genes was performed
using bioinformatics methods based on sequence similarity
between miRNAs and mRNAs. We queried TargetScan (http://
www.targetscan.org/) [67,68] and PicTar (http://pictar.mdc-
berlin.de/) [69,70]. Prediction algorithms change over time, and
the analysis included here is from May 2011.
Statistical Analysis
Each experiment was performed at least three times, and all
values in the paper are reported as means6SD. Comparisons
between groups were made with student’s t-test. While statistical
significances of mean difference among multiple groups were
performed with analysis of variance (ANOVA) followed by post
hoc Dunettes tests. And a P-value of less than 0.05 was accepted as
statistically significant.
Supporting Information
Figure S1 DNA sequencing of plasmid pcDNA-miR34a.
The restriction enzyme cutting sites of BamH I and Hind III were
underlined; the pri-miR-34a sequences were highlighted.
(PDF)
Figure S2 Proliferation, migration and invasion assay
of osteosacoma SOSP-9607 cells with transient transfec-
tion. SOSP-9607 cells were transiently transfected with 50 nM of
miR-34a mimics, mimics NC, miR-34a inhibitor and inhibitor NC
(Genepharma, China), respectively. 48 h later, the proliferation
(A, B), migration (C, D) and invasion (E, F) assay were performed.
The results were presented as means6SD. *P,0.05, **P,0.01
(n=3) were accepted as statistically significant.
(TIF)
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